Zoetis earnings release, August 6, 2026
Zoetis Announces Second Quarter 2026 Results
• Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis
• Adjusted Net Income of $781 Million, or Adjusted Diluted EPS of $1.87
• Revenue and Adjusted Net Income Declined 1% and 2%, Respectively, on an Organic Operational Basis
• Revises Full Year 2026 Revenue Guidance to $9.120 - $9.320 Billion to Organic Operational Revenue Growth of (3)% to (1)%
• Revises Full Year 2026 Adjusted Net Income Guidance to Organic Operational Growth of (9)% to (5)%
• Revises Guidance for Adjusted Diluted EPS to $6.15 - $6.25
PARSIPPANY, N.J. – August 6, 2026 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today reported its financial results for the second quarter of 2026.
The company reported revenue of $2.5 billion for the second quarter of 2026, flat compared with the second quarter of 2025, decreasing 1% on an organic operational¹ basis. Net income for the second quarter of 2026 was $691 million, or $1.65 per diluted share, decreasing 5% and growing 1%, respectively, on a reported basis.
Adjusted net income² for the second quarter of 2026 was $781 million, or $1.87 per diluted share, decreasing 1% and increasing 5%, respectively, on a reported basis, decreasing 2% and increasing 4%, respectively, on an organic operational basis. Adjusted net income for the second quarter of 2026 excludes the net impact of $90 million for purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.
"Second quarter results reflected a more pressured Companion Animal market, as lower clinic visits and pet owner price sensitivity reduced demand across parts of our portfolio and heightened competition in key categories," said Kristin Peck, Chief Executive Officer at Zoetis. "At the same time, these dynamics reinforce the enduring attractiveness of the markets Zoetis has helped define and advance. We are adapting our commercial strategy to the marketplace in front of us, deploying targeted investments, accelerating innovation, and pursuing business development to strengthen our position in areas aligned with the future of animal health. We also continue to benefit from the breadth of our diversified portfolio, including strength in Livestock and Diagnostics. As we advance our robust pipeline, including more than 12 potential blockbusters over the coming years, we are acting with urgency and
1 | remain confident in the long-term fundamentals of animal health and in Zoetis' ability to compete, lead, and create shareholder value."
SEGMENT HIGHLIGHTS
Zoetis organizes and manages its commercial operations across two segments: United States (U.S.) and International. Within these segments, the company delivers a diverse portfolio of products for companion animals and livestock, tailored to local trends and customer needs. In the second quarter of 2026
:
• Revenue in the
U.S. segment totaled $1.3 billion, decreasing 7% on both a reported and an organic operational basis relative to the second quarter of 2025. Companion animal product sales decreased 11% due to continued softer end-market demand. The company's key dermatology franchise and Simparica Trio® faced persistent macro-driven price sensitivity and heightened competitive pressure. Also contributing to the decline was the impact of generic competition on the Cerenia® and Convenia® brands, as well as lower sales of Librela®. Sales of livestock products increased 23% on both a reported and organic operational basis in the quarter, supported by strength across cattle and poultry. Cattle performance was underpinned by favorable producer economics in beef cattle and supply timing. Poultry performance benefited from increased vaccine sales tied to disease outbreak activity.
• Revenue in the
International segment was $1.2 billion, increasing 8% on a reported basis and 6% on an organic operational basis compared with the second quarter of 2025. Companion animal product sales grew 8% on a reported basis and 5% on an organic operational basis, led by the company's parasiticides portfolio, including Simparica Trio, along with contributions from Revolution® and Stronghold®. Also contributing to growth was companion animal diagnostics, as well as osteoarthritis (OA) pain with the launch of Lenivia® and Portela™, the company's long-acting monoclonal antibody pain products that provide dogs and cats with up to three months of pain relief. These gains were partially offset by lower sales of key dermatology products as well as challenging market conditions impacting the broader portfolio. Sales of livestock products grew 8% on a reported basis and 6% on an organic operational basis, driven by growth in cattle and poultry.
INVESTMENTS IN GROWTH
Zoetis continued to advance innovation across its diversified portfolio, including a pipeline with more than 12 potential blockbuster³ candidates in areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity. During the quarter, the company advanced major-market approvals, expanded access to industry-leading treatments in new geographies, enhanced diagnostics capabilities, and delivered solutions to support customers facing emerging and transboundary infectious disease threats. Together, these efforts reflect Zoetis' focus on translating science, global scale and customer insights into solutions that improve the health of companion animals and livestock around the world.
2 |
Delivering on Commitment to Innovation
Zoetis is executing on its commitment to deliver a significant approval in a major market every year for the next several years. In July, the company received marketing authorization from the European Commission for
Poulvac®
Procerta®
HVT-ND... (truncated)duction against Newcastle and Marek’s disease.
Lenivia and
Portela, long-acting monoclonal antibody therapies providing dogs and cats with up to three months of OA pain relief from a single injection, launched in Canada and the EU and were approved in Great Britain. Lenivia was also approved in Switzerland.
Supporting Prevention and Treatment of New World Screwworm
With New World screwworm now confirmed in the United States, Zoetis has been well prepared to support customers’ prevention and treatment strategies.
Dectomax®
-CA1, the first parasite control product to receive FDA conditional approval for the prevention and treatment of New World screwworm myiasis in beef cattle, together with
Dectomax®, received emergency use authorization in the U.S. for prevention of infestations in swine, sheep, deer, horses, lactating and dry dairy cows, and dairy replacement heifers. This response underscores Zoetis’ long-standing support for a One Health approach and its ability to deliver targeted solutions when disease threats affect animals, customers, and the broader food supply.
Additional approvals from the quarter include:
• Vanguard® crLyme received a label update in the U.S. for effectiveness against subclinical arthritis caused by
Borrelia burgdorferi, representing a significant pipeline acceleration.
• Bonqat®, an oral medication to help alleviate acute anxiety and fear associated with transportation and veterinary visits in cats, was approved in China.
• Synovex®
One Grower gained an expanded label approval in the U.S. to increase the rate of weight gain in growing beef steers and heifers in dry lots or on pasture with insufficient forage.
• Suvaxyn®
PRRS Needle-Free Microdose, a vaccine that helps prevent porcine reproductive and respiratory syndrome, was approved in the EU. This approval includes a needle free intramuscular administration claim and a new multidose presentation.
• Fostera®
Gold PVC MH Flex, a vaccine to help prevent infection from Mycoplasma hyopneumoniae and Porcine circovirus, was approved in Japan.
Accelerating Diagnostics Capabilities
In July, Zoetis completed the acquisition of VitalRADS, a veterinary teleradiology services platform. This milestone advances Zoetis’ strategic pursuit of opportunities that unlock new sources of growth by expanding its Global Diagnostics offering with around-the-clock access to board-certified veterinary specialists through a cloud-based teleradiology platform. The acquisition will extend Zoetis’ capabilities
3 | beyond in-vitro testing into veterinary imaging interpretation and advance its vision of a more complete end-to-end Virtual Reference Lab.
Zoetis also expanded the capabilities of
Vetscan Opticell™, making it the first and only point of care hematology analyzer to offer cellular hemoglobin mean – previously available only in reference laboratories. This expansion adds greater diagnostic depth in clinics and delivers value to veterinary teams through time, cost, and space savings.
Together, these investments strengthen Zoetis’ diagnostics capabilities and reinforce the company’s differentiated position in animal health with scale across both diagnostics and therapeutics.
Advancing Sustainability in Animal Health for a Better Future
In June, Zoetis published its 2025 Sustainability Report, marking the completion of its initial Driven to Care aspirations set in 2021 and introducing the strategy’s next phase, with an even sharper focus across Communities, Animals and the Planet. The report also highlighted that the Zoetis Foundation fulfilled its commitment to distribute $35 million in grants from 2021 to 2025, helping strengthen the animal health ecosystem by advancing opportunities for veterinary professionals and livestock farmers.
FINANCIAL GUIDANCE
Zoetis is providing updated guidance based on the current operating environment.
• Revenue of $9.120 billion to $9.320 billion
(organic operational growth of (3)% to (1)%)
• Reported net income of $2.330 billion to $2.380 billion
• Adjusted net income of $2.570 billion to $2.620 billion
(organic operational growth of (9)% to (5)%)
• Reported diluted EPS of $5.55 to $5.65
• Adjusted diluted EPS of $6.15 to $6.25
This guidance reflects foreign exchange rates as of July 21, 2026. Additional details on guidance are included in the financial tables and will be discussed on the company's conference call.
WEBCAST & CONFERENCE CALL DETAILS
Zoetis will host a webcast and conference call today at 8:30 a.m. ET to review second quarter 2026 results, discuss financial guidance and respond to questions from financial analysts. The live webcast and corresponding slides can be accessed by visiting https://investor.zoetis.com/events-presentations. A replay of the webcast will be available following the event.
About Zoetis
Zoetis is the world’s leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven
4 |
R&D, advanced manufacturing, and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.¹
Organic operational results (a non-GAAP financial measure) is defined as results excluding the impact of foreign exchange and certain acquisitions and divestitures.²... (truncated)and reported diluted earnings per share, excluding purchase accounting adjustments, acquisition and divestiture-related costs and certain significant items.³
A blockbuster has annual sales of at least $100 million.
DISCLOSURE NOTICES
Financial statements
Income Statement
Three Months Ended — (millions of dollars, except per share data)
| Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | % Change | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | % Change | ||
|---|---|---|---|---|---|---|---|
| Revenue | 2,468 | 2,474 | 4,730 | 4,672 | 1.0% | ||
| Costs and expenses: | Cost of sales | 673 | 664 | 1.0% | 1,314 | 1,282 | 2.0% |
| Costs and expenses: | Selling, general and administrative expenses | 592 | 614 | -4.0% | 1,180 | 1,188 | -1.0% |
| Costs and expenses: | Research and development expenses | 173 | 166 | 4.0% | 353 | 328 | 8.0% |
| Costs and expenses: | Amortization of intangible assets | 31 | 33 | -6.0% | 62 | 65 | -5.0% |
| Costs and expenses: | Restructuring charges and certain acquisition and divestiture-related costs | 77 | 30 | 99 | 30 | ||
| Costs and expenses: | Interest expense, net of capitalized interest | 61 | 53 | 15.0% | 123 | 107 | 15.0% |
| Costs and expenses: | Other (income)/deductions–net | -5 | 2 | -25 | -13 | 92.0% | |
| Costs and expenses: | Income before provision for taxes on income | 866 | 912 | -5.0% | 1,624 | 1,685 | -4.0% |
| Costs and expenses: | Provision for taxes on income | 175 | 186 | -6.0% | 332 | 357 | -7.0% |
| Costs and expenses: | Net income before allocation to noncontrolling interests | 691 | 726 | -5.0% | 1,292 | 1,328 | -3.0% |
| Costs and expenses: | Net income attributable to Zoetis Inc. | 691 | 726 | -5.0% | 1,292 | 1,328 | -3.0% |
| Costs and expenses: | Earnings per share attributable to Zoetis—basic | 1.65 | 1.63 | 1.0% | 3.08 | 2.98 | 3.0% |
| Costs and expenses: | Earnings per share attributable to Zoetis—diluted | 1.65 | 1.63 | 1.0% | 3.08 | 2.97 | 4.0% |
| Weighted-average shares used to calculate earnings per share | Basic | 417.6 | 445.1 | 419.9 | 446.3 | ||
| Weighted-average shares used to calculate earnings per share | Diluted | 417.7 | 445.5 | 420.1 | 446.7 |
Income Statement
7 |
| ZOETIS INC. – RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION – CERTAIN LINE ITEMS – (UNAUDITED) – (millions of dollars, except per share data) – Three Months Ended June 30, 2026 – GAAP Reported | Three Months Ended June 30, 2025 – GAAP Reported | ZOETIS INC. – RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION – CERTAIN LINE ITEMS – (UNAUDITED) – (millions of dollars, except per share data) – Three Months Ended June 30, 2026 – Purchase Accounting Adjustments | Three Months Ended June 30, 2025 – Purchase Accounting Adjustments | ZOETIS INC. – RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION – CERTAIN LINE ITEMS – (UNAUDITED) – (millions of dollars, except per share data) – Three Months Ended June 30, 2026 – Certain Significant Items(2) | Three Months Ended June 30, 2025 – Certain Significant Items(2) | |
|---|---|---|---|---|---|---|
| Cost of sales | 673 | |||||
| Gross profit | 1,795 | 1 | 3 | |||
| Selling, general and administrative expenses | 592 | -3 | -3 | |||
| Amortization of intangible assets | 31 | -26 | ||||
| Restructuring charges and certain acquisition and divestiture-related costs | 77 | -75 | ||||
| Income before provision for taxes on income | 866 | 30 | 81 | |||
| Provision for taxes on income | 175 | 6 | 17 | |||
| Net income attributable to Zoetis | 691 | 24 | 64 | |||
| Earnings per common share attributable to Zoetis–diluted | 1.65 | 0.06 | 0.16 | |||
| Cost of sales | 664 | |||||
| Gross profit | 1,810 | 1 | 2 | |||
| Selling, general and administrative expenses | 614 | -2 | -9 | |||
| Research and development expenses | 166 | -1 | ||||
| Amortization of intangible assets | 33 | -29 | ||||
| Restructuring charges and certain acquisition and divestiture-related costs | 30 | -29 | ||||
| Other (income)/deductions–net | 2 | -8 | ||||
| Income before provision for taxes on income | 912 | 33 | 48 | |||
| Provision for taxes on income | 186 | 8 | 9 | |||
| Net income attributable to Zoetis | 726 | 25 | 39 | |||
| Earnings per common share attributable to Zoetis–diluted | 1.63 | 0.06 | 0.09 |
Income Statement
8 |
| ZOETIS INC. – RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION – CERTAIN LINE ITEMS – (UNAUDITED) – (millions of dollars, except per share data) – Six Months Ended June 30, 2026 – GAAP Reported | Six Months Ended June 30, 2025 – GAAP Reported | ZOETIS INC. – RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION – CERTAIN LINE ITEMS – (UNAUDITED) – (millions of dollars, except per share data) – Six Months Ended June 30, 2026 – Purchase Accounting Adjustments | Six Months Ended June 30, 2025 – Purchase Accounting Adjustments | ZOETIS INC. – RECONCILIATION OF GAAP REPORTED TO NON-GAAP ADJUSTED INFORMATION – CERTAIN LINE ITEMS – (UNAUDITED) – (millions of dollars, except per share data) – Six Months Ended June 30, 2026 – Certain Significant Items(2) | Six Months Ended June 30, 2025 – Certain Significant Items(2) | |
|---|---|---|---|---|---|---|
| Cost of sales | 1,314 | |||||
| Gross profit | 3,416 | 2 | 5 | |||
| Selling, general and administrative expenses | 1,180 | -2 | -7 | |||
| Research and development expenses | 353 | -1 | ||||
| Amortization of intangible assets | 62 | -53 | ||||
| Restructuring charges and certain acquisition and divestiture-related costs | 99 | -95 | ||||
| Other (income)/deductions–net | -25 | -1 | ||||
| Income before provision for taxes on income | 1,624 | 58 | 108 | |||
| Provision for taxes on income | 332 | 13 | 21 | |||
| Net income attributable to Zoetis | 1,292 | 45 | 87 | |||
| Earnings per common share attributable to Zoetis–diluted | 3.08 | 0.11 | 0.21 | |||
| Cost of sales | 1,282 | |||||
| Gross profit | 3,390 | 2 | 2 | |||
| Selling, general and administrative expenses | 1,188 | -5 | -15 | |||
| Research and development expenses | 328 | -1 | ||||
| Amortization of intangible assets | 65 | -57 | ||||
| Restructuring charges and certain acquisition and divestiture-related costs | 30 | -29 | ||||
| Other (income)/deductions–net | -13 | -8 | ||||
| Income before provision for taxes on income | 1,685 | 65 | 54 | |||
| Provision for taxes on income | 357 | 15 | 9 | |||
| Net income attributable to Zoetis | 1,328 | 50 | 45 | |||
| Earnings per common share attributable to Zoetis–diluted | 2.97 | 0.12 | 0.1 |
Income Statement
Three Months Ended — (2) Certain significant items include the following:
| Three Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2025 | |
|---|---|---|---|---|
| Other restructuring charges and cost-reduction/productivity initiatives(a) | 75 | 7 | 95 | 7 |
| Business process transformation program(b) | 6 | 11 | 11 | 18 |
| Certain asset impairment charges(c) | 27 | 27 | ||
| Net loss on sale of business(d) | 3 | 3 | ||
| Other | 2 | -1 | ||
| Total certain significant items—pre-tax | 81 | 48 | 108 | 54 |
| Income taxes(e) | 17 | 9 | 21 | 9 |
| Total certain significant items—net of tax | 64 | 39 | 87 | 45 |
Income Statement
Three Months Ended — (millions of dollars)
| Three Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2026 | Six Months Ended – June 30, – 2026 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2025 | Three Months Ended – June 30, – 2025 | Six Months Ended – June 30, – 2025 | % Change – Reported Change | % Change – Foreign Exchange | % Change – Operational(b) | % Change – Organic Operational(c) | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adjusted cost of sales | 669 | 661 | 1.0% | 3.0% | -2.0% | |||||||
| as a percent of revenue | 27.1 | 26.7 | NA | NA | NA | |||||||
| Adjusted SG&A expenses | 586 | 603 | -3.0% | 1.0% | -4.0% | |||||||
| Adjusted R&D expenses | 173 | 165 | 5.0% | 1.0% | 4.0% | |||||||
| Adjusted net income | 781 | 791 | -1.0% | 1.0% | -2.0% | -2.0% | ||||||
| Adjusted cost of sales | 1,307 | 1,278 | 2.0% | 6.0% | -4.0% | |||||||
| as a percent of revenue | 27.6 | 27.4 | NA | NA | NA | |||||||
| Adjusted SG&A expenses | 1,171 | 1,168 | 2.0% | -2.0% | ||||||||
| Adjusted R&D expenses | 352 | 327 | 8.0% | 2.0% | 6.0% | |||||||
| Adjusted net income | 1,427 | 1,424 | 1.0% | -1.0% | -1.0% |
Income Statement
Selected Line Items (millions of dollars, except per share amounts) — 2026 GUIDANCE
| Full Year 2026 as of August 6, 2026 | Full Year 2026 as of May 7, 2026 (Prior Guidance) | |
|---|---|---|
| Revenue | $9,120 to $9,320 | $9,680 to $9,960 |
| Organic operational results(a) | (3)% to (1)% | 2% to 5% |
| Adjusted cost of sales as a percentage of revenue(b) | Approximately 29.0% | Approximately 28.5% |
| Adjusted SG&A expenses(b) | $2,330 to $2,380 | $2,350 to $2,400 |
| Adjusted R&D expenses(b) | $720 to $730 | $735 to $745 |
| Adjusted interest expense and other (income)/deductions-net(b) | Approximately $215 | Approximately $215 |
| Effective tax rate on adjusted income(b) | Approximately 20.5% | Approximately 20.5% |
| Adjusted diluted EPS(b) | $6.15 to $6.25 | $6.85 to $7.00 |
| Adjusted net income(b) | $2,570 to $2,620 | $2,870 to $2,950 |
| Organic operational results(a)(c) | (9)% to (5)% | 2% to 6% |
| Certain significant items and acquisition and divestiture-related costs(d) | Approximately $150 | Approximately $100 |
| Reported diluted EPS | $5.55 to $5.65 | $6.35 to $6.50 |
Income Statement
Reconciliations of 2026 reported guidance to 2026 adjusted guidance follows: (millions of dollars, except per share amounts)
| Reported | Certain significant items and acquisition and divestiture-related costs(d) | Purchase accounting | Adjusted(b) | |
|---|---|---|---|---|
| Cost of sales as a percentage of revenue | ~ 29.2% | ~ (0.2%) | ~ 29.0% | |
| SG&A expenses | $2,350 to $2,400 | ~ $(12) | ~ $(8) | $2,330 to $2,380 |
| R&D expenses | $722 to $732 | ~ $(2) | $720 to $730 | |
| Interest expense and other (income)/deductions-net | ~ $215 | ~ $215 | ||
| Effective tax rate | ~ 20.6% | ~ (0.1%) | ~ 20.5% | |
| Diluted EPS | $5.55 to $5.65 | ~ $0.38 | ~ $0.22 | $6.15 to $6.25 |
| Net income attributable to Zoetis | $2,330 to $2,380 | ~ $150 | ~ $90 | $2,570 to $2,620 |
Income Statement
12 |
| ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – Three Months Ended – June 30, – 2026 | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – Three Months Ended – June 30, – 2025 | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Reported Change | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Foreign Exchange | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Operational(b) | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Divestitures | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Organic Operational(c) | ||
|---|---|---|---|---|---|---|---|---|
| Revenue: | Companion Animal | 1,708 | 1,790 | -5.0% | 1.0% | -6.0% | -6.0% | |
| Revenue: | Livestock | 731 | 651 | 12.0% | 2.0% | 10.0% | -1.0% | 11.0% |
| Revenue: | Contract Manufacturing & Human Health | 29 | 33 | -12.0% | 1.0% | -13.0% | -13.0% | |
| Revenue: | Total Revenue | 2,468 | 2,474 | 2.0% | -2.0% | -1.0% | -1.0% | |
| U.S.: | Companion Animal | 1,044 | 1,176 | -11.0% | -11.0% | -11.0% | ||
| U.S.: | Livestock | 222 | 180 | 23.0% | 23.0% | 23.0% | ||
| U.S.: | Total U.S. Revenue | 1,266 | 1,356 | -7.0% | -7.0% | -7.0% | ||
| International: | Companion Animal | 664 | 614 | 8.0% | 3.0% | 5.0% | 5.0% | |
| International: | Livestock | 509 | 471 | 8.0% | 4.0% | 4.0% | -2.0% | 6.0% |
| International: | Total International Revenue | 1,173 | 1,085 | 8.0% | 3.0% | 5.0% | -1.0% | 6.0% |
| Companion Animal: | Dogs and Cats | 1,634 | 1,719 | -5.0% | 1.0% | -6.0% | ||
| Companion Animal: | Horses | 74 | 71 | 4.0% | 1.0% | 3.0% |
Income Statement
13 |
| ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – Six Months Ended – June 30, – 2026 | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – Six Months Ended – June 30, – 2025 | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Reported Change | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Foreign Exchange | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Operational(b) | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Divestitures | ZOETIS INC. CONSOLIDATED REVENUE BY SEGMENT(a) AND SPECIES (UNAUDITED) (millions of dollars) – % Change – Organic Operational(c) | ||
|---|---|---|---|---|---|---|---|---|
| Revenue: | Companion Animal | 3,227 | 3,331 | -3.0% | 2.0% | -5.0% | -5.0% | |
| Revenue: | Livestock | 1,451 | 1,278 | 14.0% | 4.0% | 10.0% | -1.0% | 11.0% |
| Revenue: | Contract Manufacturing & Human Health | 52 | 63 | -17.0% | 1.0% | -18.0% | -18.0% | |
| Revenue: | Total Revenue | 4,730 | 4,672 | 1.0% | 2.0% | -1.0% | -1.0% | |
| U.S.: | Companion Animal | 1,909 | 2,149 | -11.0% | -11.0% | -11.0% | ||
| U.S.: | Livestock | 447 | 390 | 15.0% | 15.0% | 15.0% | ||
| U.S.: | Total U.S. Revenue | 2,356 | 2,539 | -7.0% | -7.0% | -7.0% | ||
| International: | Companion Animal | 1,318 | 1,182 | 12.0% | 6.0% | 6.0% | 6.0% | |
| International: | Livestock | 1,004 | 888 | 13.0% | 5.0% | 8.0% | -2.0% | 10.0% |
| International: | Total International Revenue | 2,322 | 2,070 | 12.0% | 5.0% | 7.0% | -1.0% | 8.0% |
| Companion Animal: | Dogs and Cats | 3,077 | 3,196 | -4.0% | 2.0% | -6.0% | ||
| Companion Animal: | Horses | 150 | 135 | 11.0% | 3.0% | 8.0% | ||
| Companion Animal: | Total Companion Animal Revenue | 3,227 | 3,331 | -3.0% | 2.0% | -5.0% | ||
| Livestock: | Cattle | 782 | 664 | 18.0% | 4.0% | 14.0% | ||
| Livestock: | Swine | 240 | 223 | 8.0% | 4.0% | 4.0% | ||
| Livestock: | Poultry | 233 | 210 | 11.0% | 2.0% | 9.0% | ||
| Livestock: | Fish | 149 | 136 | 10.0% | 7.0% | 3.0% | ||
| Livestock: | Sheep and other | 47 | 45 | 4.0% | 7.0% | -3.0% | ||
| Livestock: | Total Livestock Revenue | 1,451 | 1,278 | 14.0% | 4.0% | 10.0% |
Income Statement
15 |
| ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) – Three Months Ended – June 30, – 2026 | ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) – Three Months Ended – June 30, – 2025 | ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) – % Change – Reported Change | ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) – % Change – Operational(b) | ||
|---|---|---|---|---|---|
| U.S.: | Revenue | 1,266 | 1,356 | -7.0% | -7.0% |
| U.S.: | Cost of Sales | 214 | 208 | 3.0% | 3.0% |
| U.S.: | Gross Profit | 1,052 | 1,148 | -8.0% | -8.0% |
| U.S.: | Gross Margin | 83.1 | 84.7 | ||
| U.S.: | Operating Expenses | 215 | 218 | -1.0% | -1.0% |
| U.S.: | U.S. Earnings | 837 | 930 | -10.0% | -10.0% |
| International: | Revenue | 1,173 | 1,085 | 8.0% | 5.0% |
| International: | Cost of Sales | 340 | 321 | 6.0% | 2.0% |
| International: | Gross Profit | 833 | 764 | 9.0% | 6.0% |
| International: | Gross Margin | 71 | 70.4 | ||
| International: | Operating Expenses | 172 | 171 | 1.0% | -2.0% |
| International: | Other (income)/deductions-net | 1 | |||
| International: | International Earnings | 661 | 592 | 12.0% | 8.0% |
| International: | Total Reportable Segments | 1,498 | 1,522 | -2.0% | -3.0% |
| International: | Other business activities(c) | -135 | -129 | 5.0% | |
| Reconciling Items: | Corporate(d) | -315 | -324 | -3.0% | |
| Reconciling Items: | Purchase accounting adjustments(e) | -30 | -33 | -9.0% | |
| Reconciling Items: | Acquisition and divestiture-related costs(f) | -2 | -1 | ||
| Reconciling Items: | Certain significant items(g) | -81 | -48 | 69.0% | |
| Reconciling Items: | Other unallocated(h) | -69 | -75 | -8.0% | |
| Reconciling Items: | Total Earnings(i) | 866 | 912 | -5.0% |
Income Statement
16 |
| ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) – Six Months Ended – June 30, – 2026 | ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) – Six Months Ended – June 30, – 2025 | ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) – % Change – Reported Change | ZOETIS INC. SEGMENT(a) EARNINGS (UNAUDITED) (millions of dollars) – % Change – Operational(b) | ||
|---|---|---|---|---|---|
| U.S.: | Revenue | 2,356 | 2,539 | -7.0% | -7.0% |
| U.S.: | Cost of Sales | 408 | 407 | ||
| U.S.: | Gross Profit | 1,948 | 2,132 | -9.0% | -9.0% |
| U.S.: | Gross Margin | 82.7 | 84 | ||
| U.S.: | Operating Expenses | 414 | 423 | -2.0% | -2.0% |
| U.S.: | U.S. Earnings | 1,534 | 1,709 | -10.0% | -10.0% |
| International: | Revenue | 2,322 | 2,070 | 12.0% | 7.0% |
| International: | Cost of Sales | 674 | 616 | 9.0% | 3.0% |
| International: | Gross Profit | 1,648 | 1,454 | 13.0% | 9.0% |
| International: | Gross Margin | 71 | 70.2 | ||
| International: | Operating Expenses | 347 | 334 | 4.0% | -1.0% |
| International: | Other (income)/deductions-net | 1 | 1 | ||
| International: | International Earnings | 1,300 | 1,119 | 16.0% | 11.0% |
| International: | Total Reportable Segments | 2,834 | 2,828 | -2.0% | |
| International: | Other business activities(c) | -276 | -262 | 5.0% | |
| Reconciling Items: | Corporate(d) | -630 | -602 | 5.0% | |
| Reconciling Items: | Purchase accounting adjustments(e) | -58 | -65 | -11.0% | |
| Reconciling Items: | Acquisition and divestiture-related costs(f) | -4 | -1 |
Full release
Forward-Looking Statements
: This press release contains forward-looking statements, which reflect the current views of Zoetis with respect to: business plans or prospects, future operating or financial performance, future guidance, future operating models; R&D costs; timing and likelihood of success; expectations regarding products, product approvals or products under development and expected timing of product launches; expectations regarding competing products; expectations regarding financial impact of divestitures; disruptions in our global supply chain; expectations regarding the performance of acquired companies and our ability to integrate new businesses; expectations regarding the financial impact of acquisitions; future use of cash, dividend payments and share repurchases; foreign exchange rates, tax rates, tariffs, changes in tax regimes and laws and any changes thereto; possible impacts of the Fiscal Year Alignment; and other future events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Zoetis expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our most recent Annual Report on Form 10-K, including in the sections thereof captioned “Forward-Looking Statements and Factors That May Affect Future Results” and “Item 1A. Risk Factors,” in our Quarterly Reports on Form 10-Q and in our Current Reports on Form 8-K. These filings and subsequent filings are available online at www.sec.gov, www.zoetis.com, or on request from Zoetis.
Use of Non-GAAP Financial Measures: We use non-GAAP financial measures, such as adjusted net income, adjusted diluted earnings per share, operational results (which exclude the impact of foreign exchange) and organic operational results (which exclude the impact of foreign exchange and certain acquisitions and divestitures), to assess and analyze our results and trends and to make financial and operational decisions. We believe these non-GAAP financial measures are also useful to investors because they provide greater transparency regarding our operating performance. The non-GAAP financial measures included in this press release should not be considered alternatives to measurements required by GAAP, such as net income, operating income, and earnings per share, and should not be considered measures of liquidity. These non-GAAP financial measures are unlikely to be comparable with non-GAAP information provided by other companies. Reconciliations of non-GAAP financial measures and the most directly comparable GAAP financial measures are included in the tables accompanying this press release and are posted on our website at www.zoetis.com.
5 |
Internet Posting of Information: We routinely post information that may be important to investors on the 'Investor Relations' section of our website at www.zoetis.com, as well as on
LinkedIn,
Facebook,
X (formerly Twitter) and
YouTube. We encourage investors and potential investors to consult our website regularly and to follow us on social media for company news and information.
ZTS-COR
ZTS-IR
ZTS-FIN
6 |